Literature DB >> 27941069

Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies.

Christina B Rasmussen, Susanne K Kjaer, Vanna Albieri, Elisa V Bandera, Jennifer A Doherty, Estrid Høgdall, Penelope M Webb, Susan J Jordan, Mary Anne Rossing, Kristine G Wicklund, Marc T Goodman, Francesmary Modugno, Kirsten B Moysich, Roberta B Ness, Robert P Edwards, Joellen M Schildkraut, Andrew Berchuck, Sara H Olson, Lambertus A Kiemeney, Leon F A G Massuger, Steven A Narod, Catherine M Phelan, Hoda Anton-Culver, Argyrios Ziogas, Anna H Wu, Celeste L Pearce, Harvey A Risch, Allan Jensen.   

Abstract

Inflammation has been implicated in ovarian carcinogenesis. However, studies investigating the association between pelvic inflammatory disease (PID) and ovarian cancer risk are few and inconsistent. We investigated the association between PID and the risk of epithelial ovarian cancer according to tumor behavior and histotype. We pooled data from 13 case-control studies, conducted between 1989 and 2009, from the Ovarian Cancer Association Consortium (OCAC), including 9,162 women with ovarian cancers, 2,354 women with borderline tumors, and 14,736 control participants. Study-specific odds ratios were estimated and subsequently combined into a pooled odds ratio using a random-effects model. A history of PID was associated with an increased risk of borderline tumors (pooled odds ratio (pOR) = 1.32, 95% confidence interval (CI): 1.10, 1.58). Women with at least 2 episodes of PID had a 2-fold increased risk of borderline tumors (pOR = 2.14, 95% CI: 1.08, 4.24). No association was observed between PID and ovarian cancer risk overall (pOR = 0.99, 95% CI: 0.83, 1.19); however, a statistically nonsignificantly increased risk of low-grade serous tumors (pOR = 1.48, 95% CI: 0.92, 2.38) was noted. In conclusion, PID was associated with an increased risk of borderline ovarian tumors, particularly among women who had had multiple episodes of PID. Although our results indicated a histotype-specific association with PID, the association of PID with ovarian cancer risk is still somewhat uncertain and requires further investigation.
© The Author 2016. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  inflammation; neoplasms; histological type; ovarian neoplasms; pelvic inflammatory disease; risk factors

Mesh:

Substances:

Year:  2016        PMID: 27941069      PMCID: PMC5209588          DOI: 10.1093/aje/kww161

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  45 in total

1.  Modeling smoking history: a comparison of different approaches.

Authors:  Karen Leffondré; Michal Abrahamowicz; Jack Siemiatycki; Bernard Rachet
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

Review 2.  Pelvic inflammatory disease.

Authors:  Robert C Brunham; Sami L Gottlieb; Jorma Paavonen
Journal:  N Engl J Med       Date:  2015-05-21       Impact factor: 91.245

3.  Self-reported pelvic inflammatory disease in the US: a common occurrence.

Authors:  S O Aral; W D Mosher; W Cates
Journal:  Am J Public Health       Date:  1985-10       Impact factor: 9.308

4.  Pelvic inflammatory disease and the risk of epithelial ovarian cancer.

Authors:  H A Risch; G R Howe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1995 Jul-Aug       Impact factor: 4.254

5.  Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk.

Authors:  Marc T Goodman; Galina Lurie; Pamela J Thompson; Katharine E McDuffie; Michael E Carney
Journal:  Endocr Relat Cancer       Date:  2008-07-30       Impact factor: 5.678

6.  Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors.

Authors:  Christina B Rasmussen; Mette T Faber; Allan Jensen; Estrid Høgdall; Claus Høgdall; Jan Blaakær; Susanne K Kjaer
Journal:  Cancer Causes Control       Date:  2013-04-25       Impact factor: 2.506

7.  Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.

Authors:  Melissa A Merritt; Adèle C Green; Christina M Nagle; Penelope M Webb
Journal:  Int J Cancer       Date:  2008-01-01       Impact factor: 7.396

8.  Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study.

Authors:  J F M Wetzels; L A L M Kiemeney; D W Swinkels; H L Willems; M den Heijer
Journal:  Kidney Int       Date:  2007-06-13       Impact factor: 10.612

9.  Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls.

Authors:  Kathryn L Terry; Stalo Karageorgi; Yurii B Shvetsov; Melissa A Merritt; Galina Lurie; Pamela J Thompson; Michael E Carney; Rachel Palmieri Weber; Lucy Akushevich; Wei-Hsuan Lo-Ciganic; Kara Cushing-Haugen; Weiva Sieh; Kirsten Moysich; Jennifer A Doherty; Christina M Nagle; Andrew Berchuck; Celeste L Pearce; Malcolm Pike; Roberta B Ness; Penelope M Webb; Mary Anne Rossing; Joellen Schildkraut; Harvey Risch; Marc T Goodman
Journal:  Cancer Prev Res (Phila)       Date:  2013-06-12

10.  Adequacy of family history taking in ovarian cancer patients: a population-based study.

Authors:  Anne M van Altena; Sandra van Aarle; Lambertus A L M Kiemeney; Nicoline Hoogerbrugge; Leon F A G Massuger; Joanne A de Hullu
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

View more
  20 in total

1.  Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis.

Authors:  Zhiyi Zhou; Fangfang Zeng; Jianhui Yuan; Jinling Tang; Graham A Colditz; Shelley S Tworoger; Britton Trabert; Xuefen Su
Journal:  Cancer Causes Control       Date:  2017-03-24       Impact factor: 2.506

2.  Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study.

Authors:  Hyo K Park; Joellen M Schildkraut; Anthony J Alberg; Elisa V Bandera; Jill S Barnholtz-Sloan; Melissa Bondy; Sydnee Crankshaw; Ellen Funkhouser; Patricia G Moorman; Edward S Peters; Paul Terry; Frances Wang; Julie J Ruterbusch; Ann G Schwartz; Michele L Cote
Journal:  Cancer Causes Control       Date:  2018-09-29       Impact factor: 2.506

3.  Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer.

Authors:  Sarah Irvin; Megan A Clarke; Britton Trabert; Nicolas Wentzensen
Journal:  Cancer Causes Control       Date:  2020-07-20       Impact factor: 2.506

4.  High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.

Authors:  Katharine K Brieger; Minh Tung Phung; Bhramar Mukherjee; Kelly M Bakulski; Hoda Anton-Culver; Elisa V Bandera; David D L Bowtell; Daniel W Cramer; Anna DeFazio; Jennifer A Doherty; Sian Fereday; Renée Turzanski Fortner; Aleksandra Gentry-Maharaj; Ellen L Goode; Marc T Goodman; Holly R Harris; Keitaro Matsuo; Usha Menon; Francesmary Modugno; Kirsten B Moysich; Bo Qin; Susan J Ramus; Harvey A Risch; Mary Anne Rossing; Joellen M Schildkraut; Britton Trabert; Robert A Vierkant; Stacey J Winham; Nicolas Wentzensen; Anna H Wu; Argyrios Ziogas; Lilah Khoja; Kathleen R Cho; Karen McLean; Jean Richardson; Bronwyn Grout; Anne Chase; Cindy McKinnon Deurloo; Kunle Odunsi; Brad H Nelson; James D Brenton; Kathryn L Terry; Paul D P Pharoah; Andrew Berchuck; Gillian E Hanley; Penelope M Webb; Malcolm C Pike; Celeste Leigh Pearce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-11-17       Impact factor: 4.090

Review 5.  Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.

Authors:  Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

6.  Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium.

Authors:  Ana Babic; Holly R Harris; Allison F Vitonis; Linda J Titus; Susan J Jordan; Penelope M Webb; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Kristine Wicklund; Marc T Goodman; Francesmary Modugno; Kirsten B Moysich; Roberta B Ness; Susanne K Kjaer; Joellen Schildkraut; Andrew Berchuck; Celeste L Pearce; Anna H Wu; Daniel W Cramer; Kathryn L Terry
Journal:  Int J Cancer       Date:  2017-09-21       Impact factor: 7.396

7.  Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology.

Authors:  Mandy Spaan; Alexandra W van den Belt-Dusebout; Cornelis B Lambalk; Hester H van Boven; Roel Schats; Marian Kortman; Frank J M Broekmans; Joop S E Laven; Evert J P van Santbrink; Didi D M Braat; Lucette A J van der Westerlaken; Ben J Cohlen; Astrid E P Cantineau; Jesper M J Smeenk; Minouche M van Rumste; Mariëtte Goddijn; Ron J T van Golde; Paul A M Meeuwissen; Carl J C M Hamilton; Gabriële M Ouwens; Miranda A Gerritsma; Michael Schaapveld; Curt W Burger; Flora E van Leeuwen
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 13.506

8.  The inflammatory potential of diet and ovarian cancer risk: results from two prospective cohort studies.

Authors:  Fred K Tabung; Tianyi Huang; Edward L Giovannucci; Stephanie A Smith-Warner; Shelley S Tworoger; Elizabeth M Poole
Journal:  Br J Cancer       Date:  2017-08-03       Impact factor: 7.640

9.  Common Analgesic Use for Menstrual Pain and Ovarian Cancer Risk.

Authors:  Naoko Sasamoto; Ana Babic; Allison F Vitonis; Linda Titus; Daniel W Cramer; Britton Trabert; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Prev Res (Phila)       Date:  2021-07-09

10.  Association of pelvic inflammatory disease (PID) with ovarian cancer: a nationwide population-based retrospective cohort study from Taiwan.

Authors:  Cherry Yin-Yi Chang; Kent Yu-Hsien Lin; Chien-Chu Huang; Wu-Chou Lin
Journal:  BMC Womens Health       Date:  2021-07-28       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.